Biotech Kite Pharma (KITE) got an upgrade to outperform from FBR Tuesday on a bullish outlook for its experimental cancer therapies. “Kite made tremendous progress in 2015, and 2016 looks to be no different, with a slew of potential meaningful milestones,” wrote analyst Ed White in his research note. He pointed to last week’s update of Kite’s phase-two trial of its chimeric antigen receptor (CAR) T-cell therapy KTE-C19 in blood cancer, in which
Biotech rivals Kite Pharma (KITE) and Juno Therapeutics (JUNO) were up Tuesday after FBR issued a bullish response to their presentations at the American Society of Hematology (ASH) conference. Analyst Ed White lifted his price target on Kite stock to 72 from 65, though he retained his rating of market perform. He made the change Monday afternoon after Kite released an update on its phase-one trial of its treatment KTE-C19 for diffuse large B-cell
Biotech Kite Pharma (KITE) acknowledged Monday that a patient in one of its clinical trials died, but said the death was unrelated to its drug candidate. Kite’s stock was pounded last week, falling 9% on Thursday and 3.5% on Friday, by a rumor of a patient death in the phase one trial of its candidate KTE-C19 in diffuse large B-cell lymphoma. On Monday, the company issued a formal update on the trial. “There was one patient death early in the